Cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and the exposure of particular phagocytosis signaling molecules on the cell surface are just a few of the distinctive morphological and biochemical features of the cell death process known as apoptosis. Apoptosis-initiated cell death is distinct from necrosis-induced cell death. Apoptotic death, in contrast, is silent and orderly. Necrotic cells are typically recognized as a danger signal by the immune system, which causes inflammation.
There are two main methods for inducing apoptotic cell death: The intrinsic pathway, also known as the Bcl-2-regulated or mitochondrial pathway, is strictly regulated by the BCL-2 family of proteins and is activated by a variety of developmental cues or cytotoxic insults, such as viral infection, DNA damage, and growth-factor deprivation.The tumor necrosis factor (TNF) receptor family members, such as Fas or TNF receptor-1 (TNFR1), which contain an intracellular death domain and can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface, are what initiate the extrinsic or death-receptor pathway. Without the involvement of the BCL-2 family, this recruitment results in the subsequent activation of downstream (effector) caspases like caspase-3, -6, or -7.
Numerous human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome), may be influenced by changes in cell survival, according to studies. Some of these diseases may not progress naturally unless specific therapies that change the apoptotic threshold are used.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V52354 | BCL6-IN-4 | 2253879-65-9 | BCL6-IN-4 is a potent inhibitor of B-cell lymphoma 6 (BCL6) with IC50 of 97 nM. |
|
V52978 | BCL6-IN-5 | 2253878-09-8 | BCL6-IN-5 is a potent inhibitor of BCL6 with pIC50 of 5.82. |
|
V85280 | BDM19 | 500273-31-4 | |
|
V52351 | Belapectin (GR-MD-02) | 1980787-47-0 | Belapectin (GR-MD-02) is a galectin-3 (Gal-3) inhibitor. |
|
V56410 | Bendamustine-d8 (SDX-105-d8 free base) | 1134803-33-0 | Bendamustine-d8 is the deuterium labelled form of Bendamustine. |
|
V52347 | Benpyrine | 2550398-89-3 | Benpyrine is a specific orally bioactive TNF-α inhibitor (antagonist) with a Kd of 82.1 μM. |
|
V52346 | Benufutamab (GEN1029) | 2109730-69-8 | Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. |
|
V56310 | Benzyl isothiocyanate-d7 (benzyl isothiocyanate d7) | 1246818-63-2 | Benzyl isothiocyanate-d7 is the deuterated form of Benzyl isothiocyanaate. |
|
V77208 | BH3 hydrochloride | BH3 HCl is a bioactive peptide that can cross the BBB (blood-brain barrier), by directly activating pro-apoptotic Bax/Bak or by neutralizing anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-XL, Bcl-w, mcl1 and A-1 ) to cause apoptosis via binding to the BH3 domain. | |
|
V54882 | BIBU1361 | 793726-84-8 | BIBU1361? causes apoptosis and inhibits autophagy. |
|
V54930 | Bid BH3 (80-99) | 505070-05-3 | Bid BH3 (80-99) is a biologically active peptide. |
|
V54931 | Bik BH3 | 505070-08-6 | Bik BH3 is a biologically active peptide. |
|
V2002 | Bilobalide | 33570-04-6 | Bilobalide (BB)is a naturally occuring and biologically active terpenic trilactoneisolated from Ginkgo biloba (GB). |
|
V54940 | Bim BH3 | 505070-06-4 | Bim BH3 is a biologically active peptide. |
|
V77202 | Biotin-COG1410 TFA | Biotin-COG1410 TFA is biotinylated COG1410. | |
|
V54964 | Biotin-DEVD-CHO | 178603-73-1 | Biotin-DEVD-CHO can be used for affinity labeling of caspase-8 after Caspase-8 cleavage in vitro. |
|
V84580 | Bisabosqual A | 180027-46-7 | |
|
V30880 | Bisdemethoxycurcumin | 33171-05-0 | (E,E)-Bisdemethoxycurcumin ((E,E)-Curcumin III) is a curcumin analogue with anti~inflammatory and anticancer activities. |
|
V56395 | Bisdemethoxycurcumin-d8 (Curcumin III-d8; Didemethoxycurcumin-d8) | 2470233-08-8 | Bisdemethoxycurcumin-d8 is the deuterium labelled form of Bisdemethoxycurcumin. |
|
V80177 | BK60106 | BK60106 is a CD99 inhibitor that directly binds to the extracellular domain of CD99. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
